Marshall Wace LLP Cuts Holdings in Replimune Group, Inc. $REPL

Marshall Wace LLP reduced its holdings in Replimune Group, Inc. (NASDAQ:REPL) by 25.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,866,524 shares of the company’s stock after selling 621,161 shares during the quarter. Marshall Wace LLP’s holdings in Replimune Group were worth $17,340,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Saturn V Capital Management LP purchased a new position in Replimune Group in the second quarter worth $1,198,000. Quadrature Capital Ltd purchased a new stake in shares of Replimune Group during the 2nd quarter worth $118,000. XTX Topco Ltd acquired a new position in shares of Replimune Group during the 2nd quarter worth $583,000. Rhumbline Advisers increased its holdings in shares of Replimune Group by 6.9% in the 2nd quarter. Rhumbline Advisers now owns 102,005 shares of the company’s stock valued at $948,000 after purchasing an additional 6,616 shares in the last quarter. Finally, Letko Brosseau & Associates Inc. acquired a new stake in shares of Replimune Group in the second quarter valued at about $100,000. Institutional investors and hedge funds own 92.53% of the company’s stock.

Analyst Upgrades and Downgrades

REPL has been the topic of several recent analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Replimune Group in a research report on Monday. JPMorgan Chase & Co. raised Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price target on the stock in a research note on Monday, October 20th. Leerink Partnrs raised Replimune Group from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 20th. Leerink Partners raised Replimune Group from a “market perform” rating to an “outperform” rating and lifted their price objective for the stock from $3.00 to $13.00 in a report on Monday, October 20th. Finally, Piper Sandler upgraded Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 target price on the stock in a research report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $9.75.

Replimune Group Stock Down 4.0%

REPL stock opened at $10.30 on Wednesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. The company’s 50 day simple moving average is $8.13 and its 200-day simple moving average is $7.58. Replimune Group, Inc. has a 12 month low of $2.68 and a 12 month high of $14.80. The firm has a market capitalization of $807.93 million, a PE ratio of -2.98 and a beta of 0.66.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Equities analysts expect that Replimune Group, Inc. will post -2.97 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, insider Konstantinos Xynos sold 7,248 shares of the business’s stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total value of $65,956.80. Following the completion of the transaction, the insider directly owned 139,685 shares of the company’s stock, valued at $1,271,133.50. The trade was a 4.93% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Christopher Sarchi sold 5,208 shares of the company’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $9.10, for a total value of $47,392.80. Following the completion of the sale, the insider owned 123,088 shares in the company, valued at $1,120,100.80. This represents a 4.06% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 22,456 shares of company stock valued at $224,650. Corporate insiders own 5.20% of the company’s stock.

Replimune Group Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.